1366p * risk-benefit index of tamoxifen and raloxifene for chemoprevention of korean breast cancer
Conclusions: Women under the age 40 had more benefit than risk from tamoxifen chemoprevention. In the postmenopausal women with a uterus, raloxifene has more favorable risk-benefit index than tamoxifen.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Authors: Chang, M. Tags: prevention and screening Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer of the Uterus | Databases & Libraries | Endometrial Cancer | Evista | Pulmonary Thromboembolism | Stroke | Study | Tamoxifen | Women